The stock of Seres Therapeutics Inc (NASDAQ:MCRB) is a huge mover today! About 337,463 shares traded hands or 12.53% up from the average. Seres Therapeutics Inc (NASDAQ:MCRB) has declined 63.20% since April 8, 2016 and is downtrending. It has underperformed by 68.85% the S&P500.
The move comes after 7 months positive chart setup for the $557.98M company. It was reported on Nov, 10 by Barchart.com. We have $19.31 PT which if reached, will make NASDAQ:MCRB worth $278.99M more.
Seres Therapeutics Inc (NASDAQ:MCRB) Ratings Coverage
Out of 5 analysts covering Seres Therapeutics Inc (NASDAQ:MCRB), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Seres Therapeutics Inc has been the topic of 12 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by H.C. Wainwright on Monday, January 25. Goldman Sachs initiated Seres Therapeutics Inc (NASDAQ:MCRB) on Tuesday, July 21 with “Neutral” rating. The stock has “Buy” rating given by Canaccord Genuity on Wednesday, July 22. H.C. Wainwright initiated Seres Therapeutics Inc (NASDAQ:MCRB) on Friday, July 29 with “Buy” rating. The firm has “Outperform” rating by Cowen & Co given on Monday, June 6. The stock has “Neutral” rating given by Bank of America on Tuesday, July 21. The rating was upgraded by Bank of America to “Buy” on Thursday, October 22. The firm has “Outperform” rating given on Friday, August 12 by FBR Capital. Leerink Swann initiated Seres Therapeutics Inc (NASDAQ:MCRB) rating on Tuesday, July 21. Leerink Swann has “Outperform” rating and $60 price target. Canaccord Genuity maintained Seres Therapeutics Inc (NASDAQ:MCRB) on Tuesday, August 25 with “Buy” rating.
According to Zacks Investment Research, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.”
More notable recent Seres Therapeutics Inc (NASDAQ:MCRB) news were published by: Fool.com which released: “Why Seres Therapeutics Inc. Is Being Obliterated Today” on July 29, 2016, also Businesswire.com with their article: “SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seres …” published on November 09, 2016, Fool.com published: “Why Seres Therapeutics Inc. Shares Are Jumping Today” on August 12, 2016. More interesting news about Seres Therapeutics Inc (NASDAQ:MCRB) were released by: Businesswire.com and their article: “MCRB SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of …” published on November 04, 2016 as well as Prnewswire.com‘s news article titled: “Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Seres Therapeutics …” with publication date: October 13, 2016.
MCRB Company Profile
Seres Therapeutics, Inc., incorporated on October 18, 2010, is a microbiome therapeutics platform company. The Firm is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Firm is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Firm is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Firm is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; non-alcoholic steatohepatitis; obesity and metabolic syndrome; other inflammatory diseases, such as Crohn’s disease; cancer chemotherapy and immune suppression; rare genetic diseases, and immune-oncology related applications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.